Microbot Medical Inc. (NASDAQ:MBOT)

Friday, August 3, 2012 | Web News
Second Quarter Financial Results Revenue from product sales increased 14% to $211,000 in the second quarter of 2012 compared to the...
See All Research...

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Shares of the company have rebounded nearly 50 percent over the last three months.

Web site: http://www.stemcellsinc.com

Last updated July 24, 2012


Market Data powered by QuoteMedia. Terms of Use